An observational study in Metastatic Breast Cancer and Advanced Breast Cancer, sponsored by Onco Medical Consult GmbH. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-05.
Sponsored by Onco Medical Consult GmbH · Observational
The aim of the IMPACT - Implementing Patients' competence in oral breast cancer therapy - study is to evaluate the effectiveness of a standardized patient education and coaching and optional eMBSR for therapy management provided by specially trained oncology nurses regarding persistence rate, side effects management and unplanned therapy interruptions in outpatient oncology care for patients under Abemaciclib treatment.
Breast cancer therapy has advanced by far over the last decade. Introduction of novel therapies as well as the introduction of mammography screening are thought to have reduced mortality over the last decade. More women are treated on an individual basis, trying to avoid toxic and non-effective therapies.
However, every year about 18.000 women are diagnosed with metastastic breast cancer in Germany. Breast cancer remains one of the main reasons for deaths among women and is the main reason for death due to cancer in younger women.
Once a tumor is metastasized, well balanced treatment decisions have to be made to take both into consideration, a high chance of tumor control and a low risk for side effects. Especially in the metastatic setting symptom control and quality of life need to be in the focus of the therapy and patient care.
Modern anticancer strategies are designed against specific molecular targets with the goal of sparing normal, non-neoplastic tissues. Choosing specific molecular targets, however, is problematic. CDK4/6 (Cyclin dependent kinase 4 and 6) are important candidate targets for therapeutic intervention.
Traditionally, anticancer therapy has been dominated by intravenous drug therapy. However, oral agents, like CDK4/6 inhibitors, provide an attractive approach to this kind of treatment and use of oral treatments is increasing. Currently, there are three CDK4/6 inhibitors that have reached clinical practice in the management of ER+ HER2- advanced disease. One of them is Ademaciclib which is approved in the US since September 2017 for "adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient's hormones".
Oral agents for cancer treatment are increasingly prescribed due to their benefits. However, this type of therapy requires a high level of self-management competence by the patient. A standardized patient education provided by physicians and oncology nurses may influence the handling of the oral agents in a positive way regarding side effects and unplanned therapy interruptions.
When it comes to oral agents, the place of treatment is the patients' home. In this treatment setting, correct treatment management cannot be utilized without identifying a patient's needs to be empowered to become an expert of his/her treatment because cancer therapies are commonly difficult to handle and the medication often shows a high risk of side effects and interactions with other drugs. Care providers are challenged by the question of how mostly elderly and multimorbid patients and their supporting relatives can be enabled with essential competencies to manage their treatment by themselves. Before patients start their cancer therapy, they are usually provided with information about the treatment by their physician. However, patients often feel overwhelmed by all the details in this stressful situation and tend to have a reduced capacity to assimilate complex information. Education and additional support at the beginning and in the course of the treatment can be a useful approach for patients to better handle this situation.
Recent studies showed the positive impact of supportive care programs on patients provided by nurses. Patient-focused motivation techniques and education performed by nurses are suitable to strengthen the patients' understanding of risks and benefits from the anti-cancer treatment and oral agents. These care programs can prevent an incorrect medication intake due to misunderstandings, lead to a decrease of treatment-related symptoms like pain and fatigue and reduce critical events. In addition, patient education can facilitate supportive care through a better communication between patient and health care provider and may advance the early detection of adverse toxicity events and foster rapid symptom management.
Mindfulness based stress reduction (MBSR) shows a positive effect on mental health in breast cancer patients. The evidence confirms that MBSR reduces anxiety, depressiveness and stress of breast cancer patients and increases the health-related quality of life. A key ingredient to reduce the damaging effects of chronic stress, reducing distress, and improving quality of life is to have patients engage in behaviors that decrease sympathetic and increase parasympathetic arousal. Studies show that MBSR have a positive effect on many systems in our body and create fundamental changes in the way the brain functions. MBSR can affect neurotransmitters (i.e. glutamate, GABA) and neuromodulators (i.e. dopamine, serotonin, epinephrine), which are essential in maintaining a healthy balance between sympathetic and parasympathetic arousal, therefore, helping to manage the stress response.
The aim of the IMPACT - Implementing Patients' competence in oral breast cancer therapy - study is to evaluate the effectiveness of a standardized patient education and coaching and optional eMBSR for therapy management provided by specially trained oncology nurses regarding persistence rate, side effects management and unplanned therapy interruptions in outpatient oncology care for patients under Abemaciclib treatment.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's planned enrollment of 212 is above the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Onco Medical Consult GmbH is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients who suffer from HR+, HER2- advanced or metastatic breast cancer treated with with orally administered commercially available, prescribed Abemaciclib in combination with an aromase inhibitor or fulvestrant as initial endocrine-based therapy or in women who have received prior endocrine therapy, thereby reflecting the current SmPC (Fachinformation Verzenios®). All treatments are prescribed and performed according to each center's medical practice. Any treatment choice or change in regimen is performed at the discretion of each treating physician.
Exclusion Criteria:
Patients in this group receive a continuous standardized MOATT based patient education and coaching and optional eMBSR (electronic Mindfulness-Based Stress Reduction) within the first 24 weeks of Abemaciclib treatment.
Patients in this group receive a patient management according local routine.
(Potential) difference in persistence rate after 24 weeks of Abemaciclib therapy in both study arms.
The primary objective of this study is to evaluate both study arms regarding the (potential) effect of patient management according to local routine versus continuous standardized patient education and coaching using the MOATT on persistence rate within the first 24 weeks of Abemaciclib treatment.
Time frame: 24 weeks
Patient decided interruptions
Total time of patient decided interruptions in days during 24 weeks of Abemaciclib therapy in both study arms.
Time frame: 24 weeks
eMSBR
The effect of eMSBR after 24 weeks of Abemaciclib therapy.
Time frame: 24 weeks
Quality of life assessed by the FACT-B (Version 4.0) questionnaires.
After weeks 2, 6, 12, 18 and 24, quality of Life (QoL) will be assessed by the FACT-B (Version 4.0) questionnaires.
Time frame: 24 weeks
Patient distress assessed via distress thermometer.
After weeks 2, 6, 12, 18 and 24, patient distress will be assessed via distress thermometer.
Time frame: 24 weeks
To assess patient reported self-efficacy: patient diary
Self-efficacy will be patient reported and surveyed through a patient dairy.
Time frame: 24 weeks
To assess patient reported side-effects.
Type and duration of side-effects will be patient reported and surveyed through a patient dairy.
Time frame: 24 weeks
To assess patient reported health related stress.
Health related stress will be patient reported and surveyed via distress thermometer questionnaire.
Time frame: 24 weeks
To assess patient reported therapy related knowledge.
Therapy related knowledge will be surveyed via MOATT (MASCC Oral Agent Teaching Tool).
Time frame: 24 weeks
Incidence of therapy interruptions.
Amount of relevant events will be surveyed through patient self-reporting via patient diary.
Time frame: 24 weeks
Duration of therapy interruptions.
Relevant events (in days) will be surveyed through patient self-reporting via patient diary.
Time frame: 24 weeks
Safety and tolerability of Abemaciclib treatment: NCI Common Toxicity Criteria Version 5.0
Incidence of adverse events and serious adverse events will be reported according to NCI Common Toxicity Criteria Version 5.0.
Time frame: 24 weeks
Efficacy between the two study arms at week 24 in routine clinical practice as assessed by Progression free survival rate (PFS).
Progression free survival (PFS) rate at 24 weeks of therapy. PFS is defined as time interval from start of therapy until progressive proven with clinical measures according to expertise and daily clinical routine or death from any cause, whichever comes first.
Time frame: 24 weeks
Efficacy between the two study arms at week 24 in routine clinical practice as assessed by Overall survival rate (OS).
Overall survival (OS) rate at 24 months is defined as the time to death from therapy start of Abemaciclib.
Time frame: 24 weeks
No study locations are listed for this record.
This study is status unknown, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Onco Medical Consult GmbH